prostate cancer
Oncology · 2006–2024
7decisions
5medicines
0carried consumer input
0individual submissions
No submission for this condition has carried consumer input, including the 4 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| leuprorelin Locally advanced (stage C) or metastatic (stage D) carcinoma of the prostate, and central precocious puberty. | Nov 2024 | Recommended | none received |
| leuprorelin Locally advanced (Stage 3) and metastatic (Stage 4) prostate cancer. Treatment of patients with advanced hormone-dependent prostate carcinoma. | Jul 2019 | Recommended with restriction | none received |
| degarelix Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate. | Mar 2017 | Recommended with restriction | none received |
| leuprorelin acetate Treatment of locally advanced (stage C) or metastatic (stage D) carcinoma of the prostate. | Jul 2015 | Recommended | none received |
| degarelix Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate. | Jul 2010 | Recommended with restriction | no section in document |
| Triptorelin Locally advanced (equivalent to Stage C) or metastatic (equivalent to Stage D) carcinoma of the prostate. | Nov 2006 | Recommended with restriction | no section in document |
| triptorelin embonate Locally advanced or metastatic carcinoma of the prostate. | Nov 2006 | Recommended with restriction | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.